Introduction
During the last two decades, the development of intensive therapy regimens, including allogeneic hematopoietic SCT (HSCT), has remarkably improved the outcome of patients with hematological diseases. 1 However, pulmonary complications, both infectious and non-infectious, remain the major cause of morbidity and mortality in these patients (40-60%). 2 The diversity of etiologies and the unspecific nature of the clinical and radiological findings observed after HSCT make invasive procedures necessary to establish a definitive diagnosis. 3 For example, diffuse alveolar hemorrhage, acute respiratory distress syndrome, heart failure, drug and radiation toxicity, bronchiolitis obliterans and idiopathic pneumonia syndrome can look similar to infectious pneumonia on radiographic examination. 3, 4 Infectious complications are more common in HSCT patients because of GVHD and the use of immunosuppression. 2 Because these patients are often fragile, immunocompromised and thrombocytopenic, lung biopsies may be questioned. 5 Flexible fiber-optic bronchoscopy with bronchoalveolar lavage (BAL) has generally been considered to be a safe and accurate procedure for the evaluation of pulmonary complications in such patients. 3, 6 In previous studies, however, the reported diagnostic yield has been highly variable and the identification of a pathogen using bronchoscopy does not seem to influence mortality. 7, 8 In this study, we evaluated the incidence, etiology and outcome of pneumonia, and the safety and value of BAL for establishing the diagnosis in patients transplanted at the Karolinska University Hospital, Stockholm.
Patients and methods

Patients and donors
Between 1998 and 2004, a total of 450 patients undergoing allogeneic HSCT at Karolinska University Hospital, Stockholm, were studied retrospectively for the incidence, etiology and outcome of pneumonia. This study was approved by the ethics committee of the Karolinska Institute (DNR 425/97). Most of the patients suffered from hematological malignancies (n ¼ 349), while 51 patients had a non-malignant disorder and 50 had solid tumors. The donors were HLA-A, HLA-B and HLA-DRB1 matched unrelated donors (n ¼ 206), HLA-identical sibling/related donors (n ¼ 180), mismatched unrelated/ related donors (n ¼ 60) and syngeneic twins in four cases. PCR sequence-specific primer high-resolution typing was used for both HLA class I and II Ags. 9 All patients and donors were screened for serological status regarding CMV, HSV, VZV, EBV, hepatitis B and C virus and HIV. The patient and donor characteristics are given in Table 1 . , n ¼ 4), 2-Gy TBI (n ¼ 37) or fractionated TBI 2 Â 3 Gy and CY (30 mg/kg, n ¼ 20) for 2 days. 10 Five patients were administered other combinations before re-transplantation. Conventional full-dose conditioning consisted of CY at 120 mg/kg in combination with BU at 16 mg/kg (n ¼ 143), 7.5-10 Gy single-dose TBI (n ¼ 39) or fractionated TBI 3 Â 4 Gy (n ¼ 97). 11 Five patients with severe aplastic anemia and sibling donors were administered 200 mg/kg CY. All patients with unrelated donors or non-malignant disorders were administered anti-thymocyte globulin for 2-5 days before transplantation. 12 As GVHD prophylaxis, 348 patients were administered CsA and four doses of MTX. During the first month, the blood CsA levels were kept at 100-150 ng/ml in patients with sibling donors and at 200-300 ng/ml in patients with matched unrelated donors. 13 In the absence of GVHD, CsA was discontinued after 3-4 months using HLA-identical sibling donors and after 6 months using unrelated donors. Other combinations consisted of CsA and mycophenolate mofetil (n ¼ 47) or prednisolone (n ¼ 13), tacrolimus in combination with mycophenolate mofetil (n ¼ 5), MTX (n ¼ 8) or rapamycin (n ¼ 11). In all, five patients were administered CsA only, nine patients a T-cell-depleted graft and four patients with a twin donor and no GVHD prophylaxis.
Conditioning and GVHD prophylaxis
Supportive care
All patients were isolated in rooms with positive air pressure during the transplantation period. Antimicrobial prophylaxis, consisting of oral ciprofloxacin twice daily combined with oral amphotericin B, was administered until engraftment. The patients with anti-HSV-IgG titers X10 000/l, or those who had had a recurrent HSV infection, were administered acyclovir prophylaxis. Cotrimoxazole, for preventing Pneumocystis jiroveci (previously Pneumocystis carinii) infection, was administered 3 times per week during the first 6 months after transplant. Fluconazole at 100 mg/day was also used as prophylaxis for fungal infections, but not on a regular basis. If a body temperature above 38.5 1C, or 38 1C at least twice within 24 h, was measured, routine blood samples for cultures were gathered. Empirical antibiotic therapy with trimethoprim/sulphamethoxazole and aminoglycoside was then instituted immediately, and later adjusted to bacterial susceptibility. Amphotericin B, 1-3 mg/kg, was usually initiated after 4-5 days of antibiotic-resistant fever.
14 CMV monitoring was performed on a weekly basis in all patients, irrespective of serological status. Pre-emptive therapy to deal with CMV infection has been used since 1990. 15 After 1991, detection of more than 10 copies (1991-2002) or 100 copies (2002) (2003) (2004) of CMV-DNA per 200 000 PBLs in two consecutive blood samples was accepted as the basis for starting the pre-emptive therapy. The patients were administered either ganciclovir at 5 mg/kg or foscarnet at 90 mg/kg twice daily for 2 weeks. Patients with CMV pneumonia were given foscarnet or gancyclovir combined with i.v. Ig. 16 Definition of pneumonia The diagnosis of pneumonia was based on the respiratory symptoms combined with increased C-reactive protein (CRP) levels, fever (X38.5 1C) and positive cultures from BAL, sputum, nasopharynx, blood and/or autopsy findings and infiltrations on chest X-ray and/or computed tomography. Proven invasive fungal disease was defined using histopathological, cytopathological or direct microscopic examination of a specimen obtained through needle aspiration or biopsy, and/or culture from a sterile sample from a normally sterile site and/or positive blood cultures yielding yeasts or moulds in the context of a compatible infectious disease process. For the diagnosis of a probable invasive fungal disease, a host factor and clinical and mycological criteria were required. 17 The galactomannan assay, or measurement of D/L arabinitol quotient or B-1.3-D-glucan, was not routinely used. CMV pneumonia was defined as the presence of symptoms of pulmonary disease combined with the detection of CMV using virus isolation, histopathological testing or immunohistochemical analysis in BAL fluid or lung tissue samples from autopsy. 18 BAL procedure BAL was performed with a flexible fiber-optic bronchoscope (Olympus Company, Tokyo, Japan), according to the previously described procedures. [19] [20] [21] Transbronchial biopsies in these patients can be hazardous because of the risk of bleeding and pneumothorax. BAL with protected brush was therefore preferred in most cases. BAL and brushing fluids were cultured for bacteria, including intracellular bacteria such as mycoplasma and chlamydia, and for mycobacteria, fungal species and viruses including CMV, HSV 1 and 2, human herpes virus 6 (HHV-6), EBV, VZV, respiratory syncytial virus, adenovirus, enterovirus, influenza virus A and B and parainfluenza virus. The presence of virus Ags in fixed cells from BAL fluid was showed by immunofluorescence, using specific viral monoclonal antibodies to virus proteins. Microscopic analysis of the smears of pelleted cells from BAL fluid was performed after staining with Gram (bacteria), Giemsa, Papanicolaou (malignant cells, virus inclusion, inflammation) and ZiehlNeelsen (mycobacteria) methods and after auramine staining (mycobacteria). The Grocott (methenamine silver) procedure was used to detect P. jiroveci and other fungal species. 19, 21 The viral and fungal cultures were most often combined with the more sensitive and rapid techniques such as PCR.
Results
The incidence of pneumonia was 40%; in a total of 450 patients studied, pneumonia was diagnosed 178 times in 167 patients.
General data on patients in whom BAL was performed BAL was performed on 68 occasions in 57 patients (35 males and 22 females, median age 40 (0.5-65) years); 51 patients were adults and 6 (11%) were children (p16 years). The median time from HSCT to pneumonia was 107 days (range 14-1472). In one child and eight adults, a BAL was performed twice, and thrice in one adult. C-reactive protein was elevated in 90%, there was fever X38.5 1C in 41% and dyspnea was reported in 65% of the BAL patients. The procedure was performed using local anesthesia in 54 cases. General anesthesia was needed in 14 BALs, four of them on children (29%). No serious complications were associated with the bronchoscopies. Transient hypoxemia and intense dry cough were observed in five and two patients, respectively. Nasopharyngeal swabs and aspirates, and sputum and blood samples for cultures, were also gathered within 5 days of the BAL procedure (range 0-5 days). The outcomes of cultures from BAL and other cultures are given in Table 2 .
Patients with positive findings from BAL BAL contributed to the diagnosis of pneumonia in 43 episodes (63%). Transbronchial biopsies in four patients did not contribute to the diagnosis. The diagnostic yield was better in patients with active GVHD (28/36, 78%) than in patients without active GVHD (15/32, 47%, P ¼ 0.01) at the time of BAL. Furthermore, the diagnostic yield was significantly better in patients on immunosuppressive treatment at the time of BAL (34/47, 72%) than in those without treatment (9/21, 43%, P ¼ 0.03). No significant difference in the diagnostic yield was observed between BAL performed early (within 90 days of HSCT; 17/28, 61%) or late (26/40, 65%, P ¼ NS). The median time from radiographic signs of pneumonia to BAL was 2 (0-15) days. In these 43 BALs, 25 different microorganisms were isolated (pathogens within the same species not counted separately). We found a total of 77 pathogens, but only 53 of these were considered relevant. Bacteria were isolated in 13 cases (24%), viruses in 28 (53%) and fungi in 12 cases (23%). BAL yielded the diagnosis, whereas cultures from other specimens were negative in 33/43 cases of pneumonia (77%). The culture from sputum yielded the same result as the culture from BAL in 5/43 cases (12%), culture from nasopharyngeal aspirates in 3/43 (7%), blood culture in Table 2 Outcomes of cultures other than BAL in 43 episodes of pneumonia in patients with positive BAL findings 
Abbreviations: BAL ¼ bronchoalveolar lavage; E. coli ¼ Escherischia coli; E. faecium ¼ Enterococcus faecium; N ¼ number of pneumonia episodes in different patients; RS ¼ respiratory syncytial virus; S. aureus ¼ Staphylococcus aureus. Pathogens within parentheses have been regarded as not causing the pneumonia. a These pathogens were also found in fluids from bronchoscopy.
2/43 (5%) and culture from nasopharyngeal swabs in 0/43. The pathogens found in BAL are summarized in Table 3 . In all, 24 microorganisms were considered irrelevant, such as coagulase-negative Staphylococcus (n ¼ 4), Corynebacterium (n ¼ 1), Prevotella species (n ¼ 1), HHV-6 (n ¼ 4), EBV (n ¼ 1), adenovirus (n ¼ 3), Candida albicans (n ¼ 5) and Candida glabrata (n ¼ 5), as in these BALs other pathogens were considered more likely to have caused the pneumonia. In the absence of positive blood cultures found simultaneously, the Candida species were rather regarded as colonization. In 34 episodes with positive findings (79%), the patients had antimicrobial treatment at the time of BAL. Thus, 9 patients had only prophylactic treatment (co-trimoxazole, and combined with fluconazole in 3/9 patients), 36 patients (84%) were on immunosuppressive medication and 7 (16%) were not, at the time of BAL. In 32 patients, the treatment was changed according to the BAL findings and in 10 cases it was continued, as the pathogen suspected initially was confirmed by BAL. In another case, however, the finding of EBV in BAL did not attract attention. BAL contributed to the diagnosis in 26 episodes (60%) in patients who recovered (n ¼ 24 patients) and to 17 episodes of pneumonia (40%) in 14 patients who died. BAL was performed twice in three patients who died. Autopsy was performed in 7/14 patients. The causes of death for all patients with pneumonia are shown in Table 4 .
Patients with negative findings from BAL In 25 BAL examinations (37%), no pathogen was found. BAL was performed within 90 days of HSCT in 11 patients with negative findings and later in 14 with negative findings; 8 of these patients had active GVHD at the time of BAL, whereas 17 had no active GVHD. In these patients, BAL was performed at a median of 6 (1-30) days after signs of pneumonia on chest X-ray or computed tomography. In four patients with negative findings and two with positive findings, the bronchoscope was not positioned in the most affected segment according to radiographic infiltrations. Twenty-three patients (92%) with negative findings were treated with an empirical multi-drug regimen at the time of BAL, and two had no treatment. In four cases (16%), organisms cultured from other fluids were considered to be the causative agents: Staphylococcus aureus, Enterococcus faecalis, Candida parapsilosis in blood cultures and Moraxella catarrhalis in sputum. In 21 episodes of pneumonia, both BAL cultures and other cultures were negative. Seventeen patients (68%) who had a negative BAL recovered and eight (32%) died. An autopsy was performed in seven of these patients.
Patients with pneumonia without BAL BAL was not performed in 110 patients with pneumonia (74 adults and 36 children; median age 35 (0.5-77) years) for the following reasons: the patient's condition was not good enough (n ¼ 38), discrete symptoms (n ¼ 22), other positive cultures (blood (n ¼ 10), nasopharynx aspirate (n ¼ 2) and nasopharyngeal swab (n ¼ 1)), early administration of antibiotics and recovery (n ¼ 3), the patient refused (n ¼ 1) and unknown reasons (n ¼ 33). C-reactive protein was elevated in 92%, and fever (X38.5 1C) in 71%. Dyspnea was reported in 41% of the patients. Antimicrobial treatment was given to all patients at the time of pneumonia. In 29/78 patients (37%) who recovered and in 25/32 patients (78%) who died, several pathogens were detected in cultures from the sputum, nasopharynx, blood and/or autopsy specimens. The diagnoses before death were mostly based on blood cultures, and after death on autopsy results. Autopsy was performed on 21 patients. The causes of death are shown in Table 4 .
Discussion
In this study, BAL was performed in only 68/178 episodes of pneumonia (38%); however, the diagnostic yield of 63% Table 3 The microorganisms found in BAL (n ¼ 53) and considered as etiology of pneumonia in 43 cases Viruses, n ¼ 28 CMV 15, HHV-6 1, HSV 2, Parainfluenza virus 1,
Abbreviations: BAL ¼ bronchoalveolar lavage; E. coli ¼ Escherischia coli; HHV-6 ¼ human herpes virus; RSV ¼ respiratory syncytial virus; S. aureus ¼ Staphylococcus aureus. was high compared with some previous studies with diagnostic yields between 31 and 49%. 5, 8, 22, 23 Other studies have shown diagnostic yields of 51-80%. 3, 19, [24] [25] [26] In total, 7 BALs were performed in children and contributed to the diagnosis in four of these. There are some difficulties associated with bronchoscopies in children, such as the frequent need for general anesthesia and difficulties in performing the procedure because of their small airways. In this study, 4 (29%) of the 14 patients who needed general anesthesia were children. For 33 patients in the group of patients with pneumonia without a BAL, the reason for not performing BAL was unclear; 9 of them (27%) were children, which may have been one reason for BAL not being performed. However, previous reports support the idea that BAL can be safely performed on pediatric HSCT patients and that overall, the benefits of BAL outweigh the risks. 27 Most of the children in our study recovered (34/42, 81%).
In the BAL group with positive diagnostic findings, the time interval between chest X-ray and the BAL procedure was shorter than in patients with negative findings (2 and 6 days, respectively, Po0.001). It also seemed important to perform BAL in the most affected segment according to the radiographic signs; in four of the patients with negative findings, the bronchoscope was incorrectly positioned. Furthermore, all nine patients with only prophylactic treatment had positive findings in BAL fluid, and more patients with negative findings than with positive findings had antimicrobial treatment at the time of BAL. These results indicate that it is important to perform BAL as early and as correctly as possible. In 32 episodes of pneumonia, the treatment was changed and in 10 episodes it could proceed according to the positive findings from BAL. Thus, these patients could be spared treatment with unnecessary, expensive and potentially toxic drugs.
In all, 53 pathogens were considered relevant, mainly viruses, and were found in BAL. There were also 24 microorganisms found, mostly Candida species, not considered relevant. Candidiasis, including candidemia, chronic disseminated candidiasis and pneumonia, is one of the major causes of morbidity and mortality in HSCT recipients. 28 However, because we lacked simultaneous candidemia and/or positive cultures from autopsy specimens from lungs, we retrospectively considered most of the findings to be a result of colonization.
In our study, CMV was the most common pathogen found. Previous studies have shown that CMV has a high relapse rate and is associated with a poor outcome, and that CMV pneumonia is the leading manifestation of late disease. 29 This agrees with our findings. We diagnosed CMV from BAL specimens in 15 episodes of pneumonia in 11 patients. There was relapse in four patients in which BAL was performed twice. In another patient, CMV was diagnosed after autopsy. Nine of these 12 patients died, 6 despite antiviral treatment. In 12 episodes, the CMV pneumonia occurred 3 months or later after HSCT.
BAL was also useful in diagnosing Aspergillus species, as the procedure established the diagnosis in 6/8 cases of Aspergillus pneumonia. Historically, the mortality rate in transplant recipients with invasive aspergillosis has been high, varying between 74 and 92%. 30 However, in our study four of the patients recovered after anti-fungal treatment, indicating that the early diagnosis by the BAL procedure was important. Invasive aspergillosis has been reported at higher rates in patients with an unrelated or HLAmismatched donor. 31, 32 In our study, however, all patients with aspergillosis had a matched donor, four patients had an HLA identical sibling and four had a matched unrelated donor.
Furthermore, HHV-6 has been shown to be capable of causing interstitial pneumonitis in this group of patients, 33 and in previous studies it has been significantly associated with the occurrence of GVHD and concurrent EBV. 34 However, only 1/5 findings of HHV-6 and 2/3 findings of EBV were considered to be the cause of pneumonia. In these cases, the pathogens were also found in autopsy specimens from the lungs. Enterococcus species, mostly resistant to all antibiotics but vancomycin, were also frequently found, especially in patients for whom BAL was not performed. All patients with enterococci, except for one, died. We have regarded this pathogen as possibly not relevant. However, some studies strongly suggest that enterococci have an etiological role in the development of pneumonia. 35 HHV-6, EBV and enterococci may have had a more important or amplifying role than commonly considered, even in cases in which other pathogens were more likely to be the causative agent.
In this study, the clinical affect of bronchoscopy with BAL was high and most of the pathogens would not have been found without this procedure. However, the mortality was somewhat higher in the BAL group: 22/57 patients (38%) died, as compared with 32/110 (29%) in the other group. This may be because BAL was not performed in most of the children, who are more likely to recover than adults, and because there were more patients with dyspnea and severe etiologies, such as CMV and aspergillosis, in patients in whom a BAL was performed. We conclude that chest X-rays and BAL should be performed as soon as possible when symptoms or signs of pneumonia appear. Gathering cultures from other locations may also help to establish the diagnosis, especially if it is not possible to perform a BAL.
